ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Divestitures (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net Proceeds	$ 858	$ 1,157	$ 748
Divestiture (Gains)/Losses	0	(211)	(9)
Royalty Income	(862)	(832)	(666)
Diabetes business - royalties
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net Proceeds	846	767	612
Divestiture (Gains)/Losses	0	0	0
Royalty Income	(862)	(810)	(622)
Mature products and other
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net Proceeds	12	390	136
Divestiture (Gains)/Losses	0	(211)	(9)
Royalty Income	$ 0	(22)	$ (44)
Mature products and other | Cheplapharm
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net Proceeds		221
Divestiture (Gains)/Losses		$ (211)